2.3 Care Planning for Special & High-Risk Patient Populations

2.3 Care Planning for Special & High-Risk Patient Populations

Perioperative care planning must be tailored to address the unique physiological, anatomical, and pharmacological vulnerabilities of special patient populations. High-risk groups—including bariatric patients, pediatric patients, geriatric patients, obstetric patients, and individuals susceptible to malignant hyperthermia (MH)—require specialized nursing interventions and clinical protocols to mitigate intraoperative morbidity and mortality.

---

Bariatric Patient Management (BMI ≥30 kg/m²)

Surgical care for patients classified as obese (BMI 30–39.9 kg/m²), morbidly obese (BMI ≥40 kg/m²), or super-obese (BMI ≥50 kg/m²) presents distinct mechanical and physiological challenges.

• Weight Capacity Verification: Perioperative nurses must verify that the operating table, transfer devices, and extensions meet or exceed patient weight requirements. Standard tables accommodate up to 400–500 lbs (181–226 kg), whereas specialized bariatric tables support up to 1,000 lbs (454 kg).
• Airway & Respiratory Mechanics: Excess adipose tissue on the chest wall and abdomen severely decreases lung compliance and Functional Residual Capacity (FRC).
  • Position the patient in a ramped position for intubation (aligning the external auditory meatus horizontally with the sternal notch) to improve laryngeal visualization.
  • Utilize Reverse Trendelenburg with a padded footboard intraoperatively to allow abdominal contents to shift gravitationally away from the diaphragm, enhancing tidal volume.
• Obstructive Sleep Apnea (OSA): Screen all bariatric patients using the STOP-Bang questionnaire. A score ≥5 indicates high risk for severe OSA, requiring continuous postoperative pulse oximetry, capnography, and avoidance of heavy opioid sedation.
• Rhabdomyolysis Risk: Prolonged tissue pressure in heavy bariatric procedures (>3 to 4 hours) can cause gluteal and thigh muscle breakdown, releasing myoglobin and causing acute kidney injury. Monitor for dark port-wine urine and elevated creatine kinase (CK).

---

Pediatric Patient Considerations (Neonates to Adolescents)

Pediatric surgical patients are not small adults; their physiological reserves and anatomical proportions differ fundamentally across developmental stages.

Physiological & Environmental Precautions:

• Thermoregulation: Neonates (<28 days) and infants (<1 year) have a large body surface-area-to-mass ratio, thin skin, and minimal subcutaneous fat. They cannot shiver effectively and rely on non-shivering thermogenesis via brown adipose tissue. This metabolic pathway consumes high amounts of oxygen and glucose, predisposing hypothermic infants to severe hypoxemia, metabolic acidosis, and hypoglycemia.
  • Room Temperature Guardrail: Increase ambient OR temperature to 24°C–26°C (75°F–78°F) for neonates and infants before bringing them into the suite.
  • Use radiant warmers, warmed irrigation solutions (37°C–40°C), fluid warmers, and inline breathing circuit humidifiers.
• Fluid & Medication Calculations: All medications and IV fluid boluses must be strictly weight-based (mg/kg or mL/kg).
  • Standard pediatric maintenance fluids follow the 4-2-1 rule: 4 mL/kg/hr for the first 10 kg of weight, 2 mL/kg/hr for the next 10 kg (11–20 kg), and 1 mL/kg/hr for each kilogram above 20 kg.

---

Geriatric Patient Care (Age ≥65 Years)

Aging causes progressive decline in homeostatic reserve across all organ systems.

---

Malignant Hyperthermia (MH) Emergency Protocol

Malignant hyperthermia (MH) is a life-threatening, pharmacogenetic disorder of skeletal muscle inherited in an autosomal dominant pattern, primarily caused by mutations in the ryanodine receptor (RYR1) gene.

Triggering Agents:

• All volatile anesthetics (isoflurane, sevoflurane, desflurane, halothane).
• The depolarizing neuromuscular blocking agent succinylcholine.
• Note: Nitrous oxide, IV induction agents (propofol, etomidate, ketamine), local anesthetics, and non-depolarizing relaxants are MH-safe.

Clinical Indicators:

• Earliest Clinical Indicators: Rapid rise in end-tidal CO2 (EtCO2 >50 mmHg) unresponsive to hyperventilation, unexplained sinus tachycardia, and masseter muscle spasm.
• Late Clinical Indicators: Rapidly rising core body temperature (1°C–2°C every 5 minutes, reaching >41°C / 105.8°F), severe muscle rigidity, hyperkalemia, myoglobinuria, and disseminated intravascular coagulation (DIC).

Crisis Management Workflow:

1. Discontinue Triggers Instantly: Alert the surgeon, stop volatile agents and succinylcholine, and call for the MH cart and help.
2. Hyperventilate: Administer 100% oxygen at maximum flow rates (>10 L/min) through a clean circuit to flush out volatile gases.
3. Administer Dantrolene Sodium:
   • Dantrolene is the specific antidote that binds RYR1 receptors and halts calcium release.
   • Standard Formulation (Dantrium/Revonto): Initial dose 2.5 mg/kg IV push. Each 20 mg vial must be reconstituted with 60 mL of sterile water without a bacteriostatic agent. Repeat IV push doses up to 10 mg/kg total until hypermetabolism subsides.
   • Concentrated Formulation (Ryanodex): Initial dose 2.5 mg/kg IV push. Each 250 mg vial is reconstituted with only 5 mL of sterile water, allowing rapid push within seconds.
4. Cool the Patient: Initiate active cooling with cold IV saline, iced nasogastric/abdominal lavage, and ice packs to axillae, groin, and neck. Stop cooling when core temperature drops below 38.0°C (100.4°F) to prevent iatrogenic hypothermia.
5. Treat Hyperkalemia & Acidosis: Administer sodium bicarbonate for metabolic acidosis, IV regular insulin with 50% dextrose, and calcium chloride for severe hyperkalemic cardiac dysrhythmias.

---

Obstetric Patient Considerations (Pregnancy >20 Weeks)

When caring for a pregnant surgical patient past 20 weeks gestation, position the patient with a 15-degree left uterine displacement (LUD) by placing a firm wedge under the right hip. This displaces the heavy gravid uterus off the inferior vena cava and abdominal aorta, preventing aortocaval compression, maternal hypotension, decreased uteroplacental perfusion, and fetal distress.